Our Lady of the Lake was one of a number of medical centers nationwide studying and comparing the differences between a long-established medication used to treat heart failure with a drug called Entresto.

Clinical research at Our Lady of the Lake helps validate breakthrough heart drug

Our Lady of the Lake’s cardiology team recently participated in a clinical trial of a new drug for treating acute heart failure.

Our Lady of the Lake was one of a number of medical centers nationwide studying and comparing the differences between a long-established medication used to treat heart failure with a drug called Entresto.

Patients who were given the new drug were more likely to survive acute heart failure, require less extensive treatment and go home sooner than patients treated with standard medications. The research was published in the New England Journal of Medicine and presented at an American Heart Association scientific conference.

“The findings mean cardiologists now have an effective new early therapy for hospitalized patients with heart failure,” said Denzil Moraes, MD, a cardiologist with Louisiana Cardiology Associates and the principle study investigator in Baton Rouge.

“This is good news that will aid in the future treatment of our patients,” Dr. Moraes said. “As a leader in cardiovascular care, it’s exciting to be a part of progress and opportunities for our patients with decompensated heart failure.”

For more information about Our Lady of the Lake’s clinical trials, click here.